How International Real-World Experience Can Inform Canadian Market Access Decision-Making

As innovative medicines increasingly launch in the United States years before reaching the Canadian market, stakeholders have a growing opportunity to leverage evidence generated outside Canada to address uncertainty in market access decision-making. Real-world experience can provide valuable insight into treatment patterns, persistence, adverse event management, medical resource utilization, and budget impact before reimbursement decisions are made. 

Explore how international evidence can help manufacturers reduce uncertainty for payers, and HTA organizations, strengthen decision-making, and support access planning. Gain practical insights to help you: 

• Understand how international experience can complement clinical and economic evidence 
• Evaluate how real-world utilization, medical resource use, and adverse event management can inform access decisions 
• Assess how evolving standards of care and competitive market dynamics influence reimbursement uncertainty 
• Determine where international evidence can strengthen payer engagement, budget impact assumptions, and launch planning 
• Explore how evidence generated prior to Canadian launch can support more informed access decisions 

Learn how international real-world experience can help reduce uncertainty, strengthen market access decision-making, and support sustainable access to innovation in Canada.